Drug Trial Radar · NCT07674940
A Trial to Assess TEV-56286 at Different Doses in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
69
Planned (sponsor's estimate)
Start
Jun 26, 2026
Primary completion
Jan 15, 2027
Study completion Jan 22, 2027
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
- Sponsor type
- Industry
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the trial is to evaluate the pharmacokinetics, safety, and tolerability of TEV-56286 at different doses. The main objective is to describe how TEV-56286 is absorbed, distributed, and removed from the body (the pharmacokinetics) following administration of TEV-56286 in single doses of increasing amounts and multiple doses in healthy participants. A secondary objective is to assess the safety of TEV-56286 and how well it is tolerated. The estimated duration for participants in Part 1 with Single Ascending Dose is approximately 58 days; including up to 45 days of screening, a 4-day in-clinic period, and follow-up 8+/-1 days post discharge from the clinical unit. The estimated duration for participants in Part 2 with Multiple Ascending Dose is approximately 64 days; including up to 45 days of screening, a 10-day in-clinic period, and follow-up 8+/-1 days post discharge from the clinical unit.
Conditions
- Healthy Volunteers
Interventions
TEV-56286Drug
oral administration
PlaceboDrug
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAD: Time to maximum observed plasma drug concentration (tmax) of TEV-56286Time frame: Day 1 to Day 3
- SAD: Maximum observed plasma concentration (Cmax) of TEV-56286Time frame: Day 1 to Day 3
- SAD: Area Under the Plasma Drug Concentration-Time Curve from Time 0 to the Time of the Last Measurable Concentration (AUC0-t) of TEV-56286Time frame: Day 1 to Day 3
- SAD: Area Under the Plasma Drug Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of TEV-56286Time frame: Day 1 to Day 3
- MAD: tmax of TEV-56286Time frame: Day 7 to Day 9
- MAD: Cmax of TEV-56286Time frame: Day 7 to Day 9
- MAD: AUC0-t of TEV-56286Time frame: Day 7 to Day 9
- MAD: Area Under the Plasma Drug Concentration-Time Curve for the Defined Interval Between Doses (AUC0-tau) of TEV-56286Time frame: Day 7 to Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Teva Investigational Site 12174
Miramar, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.